Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fusion Pharmaceuticals Inc FUSN

Healthcare Biotechnology
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by... see more

Recent & Breaking News (NDAQ:FUSN)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, LABP, SWAV, FUSN

Accesswire 7 hours ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT

PR Newswire 13 days ago

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

PR Newswire 13 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA

PR Newswire April 5, 2024

SHAREHOLDER ALERT: Weiss Law Investigates Fusion Pharmaceuticals Inc.

Accesswire April 4, 2024

Lifshitz Law PLLC Announces Investigations of FUSN, DRQ, MINM, and SCX

Accesswire March 26, 2024

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN

PR Newswire March 26, 2024

INVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE

PR Newswire March 25, 2024

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Fusion Pharmaceuticals Inc. Buyout

Newsfile March 25, 2024

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, X

PR Newswire March 21, 2024

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, EVBG, FREE

Accesswire March 20, 2024

Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm

PR Newswire March 20, 2024

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

PR Newswire March 20, 2024

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FUSN, DRQ, KAMN

Accesswire March 20, 2024

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

Business Wire March 19, 2024

Fusion Pharmaceuticals shares soar 97% after AstraZeneca takeover

Jocelyn Aspa March 19, 2024

FUSN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Fusion Pharmaceuticals Inc. Is Fair to Shareholders

Business Wire March 19, 2024

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer

PR Newswire March 19, 2024

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 6, 2024

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

PR Newswire March 5, 2024